|FOR IMMEDIATE RELEASE
Wednesday, December 22, 1999
NIAID Renews Funding for the Adult AIDS Clinical Trials Group
- shown how new combinations of drug regimens can help people who have
responded poorly to or exhausted other approaches;
- proven the value of HIV-1 RNA levels in the blood as markers of how far
the disease has progressed and how beneficial treatments have been;
- identified the significance of antiretroviral drug resistance and the
reservoirs where HIV remains impervious to treatment;
- contributed to the understanding of how HIV destroys immune function and
how the immune system can be restored following HAART;
- identified regimens for treating and preventing opportunistic infections;
- improved access to clinical trials for women and underrepresented
populations within the network's academic and community-based clinical
Among the future priorities for the AACTG are defining the most effective
antiretroviral treatment strategies at each stage of HIV infection,
developing new ways to prevent or treat opportunistic infections, and
focusing on the growing problem of hepatitis C co-infection with HIV
disease. Researchers also will study the interaction between various
anti-HIV drugs and seek to lessen metabolic abnormalities and other side
effects associated with HAART.
Developing strategies to eliminate reservoirs where HIV lingers within the
body will be another important focus. Network clinicians will explore new
approaches to augment the immune system in the presence of HIV and will
examine promising leads into restoring immune function. The long-term
effects of anti-HIV therapeutics will be further scrutinized as the AACTG
seeks to improve patients' abilities to tolerate these therapies.
Press release, fact sheets and other NIAID materials are available on the
NIAID web site at www.niaid.nih.gov.
The AACTG is an outgrowth of NIAID's first major program to evaluate
potential treatments for people with AIDS, which began in the summer of
1986. In 1996, the original AIDS Clinical Trials Group branched into two
separate programs, the Adult AIDS Clinical Trials
Group and the Pediatric AIDS Clinical Trials Group (PACTG). Since 1986,
more than 50,000 volunteers have enrolled in AACTG studies, and almost
18,000 children and pregnant women have participated in PACTG studies.
NIAID supports a broad program in HIV therapeutic research. This ranges
from basic laboratory science to bench-to-bedside studies, which test new
approaches in small numbers of people, to larger clinical trials that
recruit patients throughout the country to evaluate the best new ways to
treat and manage HIV disease. In addition to the AACTG and the PACTG, other
NIAID-sponsored therapeutic research programs include the Acute Infection
and Early Disease Research Program, the Terry Beirn Community Program for
Clinical Research on AIDS, and the Integrated Preclinical/Clinical
Therapeutics Research Program.
AACTG Adult Clinical Trials Units and Principal Investigators
- University of Alabama at Birmingham - Michael S. Saag, M.D.
- Stanford University - Thomas C. Merigan, Jr., M.D.
- University of California Los Angeles - Ronald T. Mitsuyasu, M.D.
- University of California San Diego - Diane Havlir, M.D.
- University of California San Francisco - Mark Jacobson, M.D.
- University of Southern California Medical Center - John M. Leedom, M.D.
- University of Colorado Health Sciences Center - Robert T. Schooley, M.D.
- University of Miami School of Medicine - Margaret A. Fischl, M.D.
- University of Hawaii - Cecila M. Shikuma, M.D.
- Northwestern University - Robert L. Murphy, M.D.
- Indiana University - Joseph L. Wheat, M.D.
- Johns Hopkins University School of Medicine - John G. Bartlett, M.D.
- Harvard Medical School - Martin S. Hirsch, M.D.
- University of Minnesota Medical School - Henry H. Balfour, Jr., M.D.
- Washington University - William G. Powderly, M.D.
- Beth Israel Medical Center - Donna Mildvan, M.D.
- Columbia University - Scott M. Hammer, M.D.
- New York University Medical Center - Fred T. Valentine, M.D.
- University of Rochester Medical Center - Richard C. Reichman, M.D.
- Duke University - John A. Bartlett, M.D.
- University of North Carolina at Chapel Hill - Charles M. van der Horst,
- Case Western Reserve University - Michael M. Lederman, M.D.
- Ohio State University Medical Center - Robert J. Fass, M.D.
- University of Cincinnati - Judith T. Feinberg, M.D.
- University of Pennsylvania - Harvey M. Friedman, M.D.
- University of Pittsburgh - John W. Mellors, M.D.
- The Miriam Hospital - Timothy P. Flanigan, M.D.
- Vanderbilt University School of Medicine - David W. Haas, M.D.
- *University of Texas Medical Branch - Richard B. Pollard, M.D.
- University of Texas Southwestern Medical Center - Richard A. Koup, M.D.
- University of Washington - Ann C. Collier, M.D.
- University of Puerto Rico School of Medicine - Jorge L. Santana, M.D.